CAR-T 세포 치료제
Chimeric Antigen Receptor-T Cell Therapy
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Chimeric antigen receptor (CAR) T-cell therapy constitutes a revolutionary advancement in personalized cancer treatment. During this treatment, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. CAR-T cells are then expanded for clinical use and infused back into the patient's body to attack cancer. CAR-T cells have produced remarkable clinical responses with B-cell malignancies. However, CAR-T cells therapy is not without problems. Barriers to effective CAR-T cells therapy include severe life-threatening toxicities and modest anti-tumor activity. In this review, we introduce the concept of CAR-T cells therapy, currently available CAR-T cells therapy options, and how to deal with adverse events.
Abstract
Chimeric antigen receptor (CAR) T-cell therapy constitutes a revolutionary advancement in personalized cancer treatment. During this treatment, a patient's own T cells are genetically engineered to express a synthetic receptor that binds a tumor antigen. CAR-T cells are then expanded for clinical use and infused back into the patient's body to attack cancer. CAR-T cells have produced remarkable clinical responses with B-cell malignancies. However, CAR-T cells therapy is not without problems. Barriers to effective CAR-T cells therapy include severe life-threatening toxicities and modest anti-tumor activity. In this review, we introduce the concept of CAR-T cells therapy, currently available CAR-T cells therapy options, and how to deal with adverse events.
참고문헌 (28)
- June CH, "CAR T cell immunotherapy for human cancer", Science, 359, pp.1361~1365 (2018)
- Neelapu SS, "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma", N Engl J Med, 377, pp.2531~2544 (2017)
- Schuster SJ, "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma", N Engl J Med, 380, pp.45~56 (2019)
- Maude SL, "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia", N Engl J Med, 378, pp.439~448 (2018)
- Abramson JS, "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study", Lancet, 396, pp.839~852 (2020)
- Wang M, "KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma", N Engl J Med, 382, pp.1331~1342 (2020)
- Munshi NC, "Idecabtagene vicleucel in relapsed and refractory multiple myeloma", N Engl J Med, 384, pp.705~716 (2021)
- Raje N, "Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma", N Engl J Med, 380, pp.1726~1737 (2019)
- Brentjens RJ, "Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15", Nat Med, 9, pp.279~286 (2003)
- Mohanty R, "CAR T cell therapy : a new era for cancer treatment(review)", Oncol Rep, 42, pp.2183~2195 (2019)
- Joseph W. Fischer, "CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities", Frontiers in Immunology, 12 (2021), Frontiers Media SA[DOI]
- Wang K, "CD19 : a biomarker for B cell development, lymphoma diagnosis and therapy", Exp Hematol Oncol, 1, pp.36~ (2012)
- Cho SF, "Targeting B cell maturation antigen(BCMA)in multiple myeloma : potential uses of BCMA-based immunotherapy", Front Immunol, 9, pp.1821~ (2018)
- Locke FL, "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial", Lancet Oncol, 20, pp.31~42 (2019)
- "Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma (BELINDA)" (2021)[URL]
- Nastoupil LJ, "Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma : results from the US lymphoma CAR T consortium", J Clin Oncol, 38, pp.3119~3128 (2020)
- Locke FL, "Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma", N Engl J Med, 386, pp.640~654 (2022)
- "A study to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (TRANSFORM)" (2021)[URL]
- Moreaux J, "BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone", Blood, 103, pp.3148~3157 (2004)
- Sanchez E, "Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival", Br J Haematol, 158, pp.727~738 (2012)
- Mikkilineni L, "CAR T cell therapies for patients with multiple myeloma", Nat Rev Clin Oncol, 18, pp.71~84 (2021)
- Berdeja JG, "Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b", 2 open-label study, 2021, pp.398, 314~324
- "Study evaluating the safety and efficacy of JCARH125 in subjects with relapsed and/or refractory multiple myeloma (EVOLVE)" (2021)[URL]
- Lee DW, "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells", Biol Blood Marrow Transplant, 25, pp.625~638 (2019)
- Lee DW, "Current concepts in the diagnosis and management of cytokine release syndrome", Blood, 124, pp.188~195 (2014)
- Du M, "Biomarkers in individualized management of chimeric antigen receptor T cell therapy", Biomark Res, 8, pp.13~ (2020)
- Adkins S, "CAR T-cell therapy : adverse events and management", J Adv Pract Oncol, 10(Suppl 3), pp.21~28 (2019)
- Sterner RC, "CAR-T cell therapy : current limitations and potential strategies", Blood Cancer J, 11, pp.69~ (2021)